Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680
ALKS' phase II Vibrance-3 study investigates the safety and efficacy of ALKS 2680 versus placebo for treating adults with idiopathic hypersomnia.
Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition?
ALKS' set of proprietary products, Vivitrol, Aristada and Lybalvi, is driving the top-line. However, stiff competition in the target remains a woe.
GE Aerospace Leads Five Stocks Near Buy Points With This Bullish Trait
GE Aerospace has formed a flat base, one of several stocks with strong relative strength near buy points and with relatively low volatility. The post GE Aerospace Leads Five Stocks Near Buy Points With This Bullish Trait appeared first on Investor's Business Daily.
Why Is Alkermes (ALKS) Down 6.6% Since Last Earnings Report?
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?
Alkermes' Neuroscience Pivot: ALKS 2680 Set To Revolutionize Narcolepsy Treatment
Alkermes' Neuroscience Pivot: ALKS 2680 Set To Revolutionize Narcolepsy Treatment
Alkermes' Q4 Earnings & Revenues Surpass Estimates, Stock Up
ALKS reports better-than-expected fourth-quarter 2024 results. Net sales of proprietary products increase year over year.
Alkermes plc (ALKS) Q4 2024 Earnings Call Transcript
Alkermes plc (NASDAQ:ALKS ) Q4 2024 Earnings Conference Call February 12, 2025 8:00 AM ET Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs and Investor Relations Richard Pops - Chairman and Chief Executive Officer Blair Jackson - Executive Vice President and Chief Operating Officer Todd Nichols - Senior Vice President and Chief Commercial Officer Conference Call Participants Paul Matteis - Stifel Charles Duncan - Cantor Fitzgerald Umer Raffat - Evercore ISI Jessica Fye - JPMorgan Chris Shibutani - Goldman Sachs Marc Goodman - Leerink Partners Uy Ear - Mizuho Securities Troy Langford - TD Cowen Douglas Tsao - H.C. Wainwright Joel Beatty - Baird Operator Greetings, and welcome to the Alkermes Fourth Quarter 2024 Financial Results Conference Call.
Alkermes Plc EPS Soars Past Forecasts
Alkermes (ALKS 2.50%), a biopharmaceutical company known for its innovative drugs targeting mental health and neurological disorders, announced its Q4 2024 earnings on Feb. 12. The company reported robust financial results, beating analyst estimates with a non-GAAP EPS of $1.04 against an expected $0.76.
Alkermes (ALKS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Alkermes (ALKS) Q4 Earnings and Revenues Surpass Estimates
Alkermes (ALKS) came out with quarterly earnings of $1.04 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.48 per share a year ago.
What Analyst Projections for Key Metrics Reveal About Alkermes (ALKS) Q4 Earnings
Beyond analysts' top -and-bottom-line estimates for Alkermes (ALKS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term Growth
Alkermes has shifted from royalty-based revenues to proprietary product sales, driven by strong growth in Lybalvi, Vivitrol, and Aristada. ALKS 2680, a Phase 2 orexin-2 receptor agonist for narcolepsy and hypersomnia, represents a transformative opportunity in a $7.3 billion market by 2032. With $908.9 million in liquidity and a positive cash flow of $73.3 million in Q3, Alkermes can effectively fund R&D and operations.
